ZD1839 (Iressa) in non-small-cell lung cancer.
The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in a number of processes that are key to tumor progression, including cell proliferation, angiogenesis, metastatic spread, and inhibition of apoptosis. EGFR is expressed or overexpressed in non-small-cell lung cancer (NSCLC), and EGFR-mediated growth has been associated with advanced disease and poor prognosis in NSCLC patients. ZD1839 (Iressa) is an orally active, selective EGFR-tyrosine kinase inhibitor that blocks EGFR signal transduction. In preclinical studies using NSCLC cell lines, ZD1839 has been shown to inhibit tumor cell growth. In addition, ZD1839, as monotherapy and in combination with commonly used cytotoxic agents, has produced growth delay in NSCLC human xenografts. Preliminary results from phase I trials in patients with advanced disease have shown that ZD1839 has excellent bioavailability, an acceptable tolerability profile, and promising clinical activity in patients with a variety of tumor types, particularly in NSCLC. ZD1839 is currently in phase III clinical development for the treatment of advanced NSCLC.
Herbst
R S
RS
Department of Thoracic/Head and Neck Medical Oncology, UT M.D. Anderson Cancer Center, Houston, Texas 77030, USA. rherbst@mail.mdanderson.org
Khuri
F R
FR
Fossella
F V
FV
Glisson
B S
BS
Kies
M S
MS
Pisters
K M
KM
Riddle
J R
JR
Terry
K A
KA
Lee
J S
JS